Sep 15, 2013 by Max Macaluso and Dave WilliamsonKey Problems Behind Teva's Lackluster 2013Why are shares of Teva up only 2.7% since the start of 2013?
Sep 10, 2013 by Max Macaluso and Dave WilliamsonMarket Checkup: 2 Turnaround Stories to WatchThe Motley Fool's health care show, Market Checkup, for Sept. 9, 2013.
Sep 9, 2013 by Max Macaluso and Dave WilliamsonWhat Are the Main Threats to AbbVie's Humira?A look at the AbbVie's second-quarter results and the pros and cons of selling the world's biggest blockbuster drug.
Aug 30, 2013 by Max Macaluso and Dave WilliamsonJohnson & Johnson's Earnings Made EasyA run-down of this well-known health-care company's second-quarter results.
Aug 30, 2013 by Max Macaluso and Dave WilliamsonCatalysts Merck Investors Need to WatchWhich events do Merck investors need to pay close attention to?
Aug 29, 2013 by Max Macaluso and Dave WilliamsonDid This Big Pharma Giant Sink or Swim Last Quarter?A look at Pfizer's top and bottom lines in the second quarter.
Aug 29, 2013 by Max Macaluso and Dave WilliamsonMarket Checkup: Spotlight on GileadThis edition of the Fool's health care show focuses on biotech company Gilead.
Aug 29, 2013 by Max Macaluso and Dave WilliamsonMarket Checkup: Spotlight on AbbVieA deep dive into AbbVie, a brand new company with a long history.
Aug 27, 2013 by Max Macaluso and Dave WilliamsonOne More Big Pharma Bribery Scandal?Another drugmaker faces claims of misconduct in China.
Aug 26, 2013 by Max Macaluso and Dave WilliamsonWhy Rigel Investors Had a Dose of Disappointment TodayShares of Rigel slid more than 13%. Where does this biotech stand today?
Aug 26, 2013 by Max Macaluso and Dave WilliamsonThe Biotech Buyout Investors Have Been Waiting ForIt's official: Amgen is acquiring Onyx Pharmaceuticals.
Aug 26, 2013 by Max Macaluso and Dave WilliamsonMarket Checkup: A Biotech Buyout and Another Big Pharma Scandal Brewing in China?The Motley Fool's health-care show "Market Checkup" for Aug. 26, 2013.
Aug 22, 2013 by Max Macaluso and Dave Williamson3 Reasons to Buy Bristol-Myers SquibbShares of this drugmaker have been on a steady rise since the start of 2013 -- are there any reasons left to buy?
Aug 21, 2013 by Max Macaluso and Dave WilliamsonOpportunities Bristol-Myers Squibb Investors Need to WatchWhat are Bristol-Myers Squibb's biggest opportunities?
Aug 21, 2013 by Max Macaluso and Dave WilliamsonWhat's Behind Bristol-Myers Squibb's High Valuation?Shares of Bristol-Myers Squibb have soared this year --- but what's been driving this growth?
Aug 20, 2013 by Max Macaluso and Dave WilliamsonMarket Checkup: An In-Depth Look at Bristol-Myers SquibbA close look at pharmaceutical company Bristol-Myers Squibb's last quarter, upcoming catalysts, and reasons to buy and sell the stock.
Aug 15, 2013 by Max Macaluso and Dave WilliamsonMarket Checkup: Headlines for August 15, 2013The Motley Fool's health-care show, "Market Checkup," for August 15, 2013.
Aug 14, 2013 by Max MacalusoMerck's Second Quarter: Highlights Investors Need to KnowMerck's total revenue dropped more than 10%, but it wasn't all bad for the drugmaker last quarter.
Aug 13, 2013 by Max Macaluso and Dave WilliamsonTime to Panic About Pfizer's Upcoming Patent Expirations?Intellectual property is the lifeblood of the pharmaceutical industry -- how is Pfizer's patent portfolio holding up?
Aug 13, 2013 by Max Macaluso and Dave WilliamsonMarket Checkup: Johnson & Johnson's Second QuarterThe Motley Fool's health-care show Market Checkup for August 13, 2013.
